Balincan USA, Inc.
BCNN · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $256 | $626 | $18,452 | $112 |
| - Cash | $0 | $117 | $60 | $0 |
| + Debt | $0 | $1,746 | $1,122 | $447 |
| Enterprise Value | $256 | $2,255 | $19,515 | $558 |
| Revenue | $2,692 | $2,036 | $2,773 | – |
| % Growth | 32.2% | -26.6% | – | – |
| Gross Profit | $1,037 | $794 | $1,135 | – |
| % Margin | 38.5% | 39% | 40.9% | – |
| EBITDA | -$558 | -$2,311 | -$153 | – |
| % Margin | -20.7% | -113.5% | -5.5% | – |
| Net Income | -$3,749 | $709 | -$204 | – |
| % Margin | -139.3% | 34.8% | -7.4% | – |
| EPS Diluted | -0.019 | 0.009 | -0.009 | – |
| % Growth | -308.8% | 196.8% | – | – |
| Operating Cash Flow | – | -$161 | $256 | – |
| Capital Expenditures | – | -$579 | -$288 | – |
| Free Cash Flow | – | -$740 | -$32 | – |